CD34 and neoplasm: In either case, these data suggest the feasibility of developing xenograft (PDX) comprised of autologous tumor immunografts using CD34+ cells and a tumor from the same patient co-engrafted, and allowing for therapeutic assessment of new therapeutic modalities.